KR100512018B1 - 상동 재조합에 의해 인간 세포에서 인간 변이 단백질을 생성시키는 방법 - Google Patents
상동 재조합에 의해 인간 세포에서 인간 변이 단백질을 생성시키는 방법 Download PDFInfo
- Publication number
- KR100512018B1 KR100512018B1 KR10-2000-7000697A KR20007000697A KR100512018B1 KR 100512018 B1 KR100512018 B1 KR 100512018B1 KR 20007000697 A KR20007000697 A KR 20007000697A KR 100512018 B1 KR100512018 B1 KR 100512018B1
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- human
- cells
- cell
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000006801 homologous recombination Effects 0.000 title claims abstract description 22
- 238000002744 homologous recombination Methods 0.000 title claims abstract description 22
- 210000005260 human cell Anatomy 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 102000008300 Mutant Proteins Human genes 0.000 title abstract 2
- 108010021466 Mutant Proteins Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 229920001184 polypeptide Polymers 0.000 claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 36
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 71
- 150000007523 nucleic acids Chemical class 0.000 claims description 57
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 7
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 108010022394 Threonine synthase Proteins 0.000 claims description 6
- 108010025815 Kanamycin Kinase Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000013595 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Chemical group 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Chemical group 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Chemical group 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 102000002467 interleukin receptors Human genes 0.000 claims description 2
- 108010093036 interleukin receptors Chemical group 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 claims 1
- 102000047823 human PLAT Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 16
- 102000003839 Human Proteins Human genes 0.000 description 10
- 108090000144 Human Proteins Proteins 0.000 description 10
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 101150010939 tpa gene Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97112639 | 1997-07-23 | ||
| EP97112639.6 | 1997-07-23 | ||
| PCT/EP1998/004583 WO1999005264A2 (de) | 1997-07-23 | 1998-07-22 | Herstellung humaner mutierter proteine in humanen zellen mittels homologer rekombination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010022127A KR20010022127A (ko) | 2001-03-15 |
| KR100512018B1 true KR100512018B1 (ko) | 2005-09-02 |
Family
ID=8227102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2000-7000697A Expired - Lifetime KR100512018B1 (ko) | 1997-07-23 | 1998-07-22 | 상동 재조합에 의해 인간 세포에서 인간 변이 단백질을 생성시키는 방법 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6444441B1 (enExample) |
| EP (1) | EP1000167B2 (enExample) |
| JP (1) | JP2001511341A (enExample) |
| KR (1) | KR100512018B1 (enExample) |
| CN (2) | CN101348789B (enExample) |
| AR (2) | AR013251A1 (enExample) |
| AT (1) | ATE313643T1 (enExample) |
| AU (1) | AU729489B2 (enExample) |
| BR (1) | BR9811531A (enExample) |
| CA (1) | CA2297660C (enExample) |
| DE (1) | DE59813296D1 (enExample) |
| DK (1) | DK1000167T4 (enExample) |
| ES (1) | ES2255177T5 (enExample) |
| PT (1) | PT1000167E (enExample) |
| TR (1) | TR200000172T2 (enExample) |
| WO (1) | WO1999005264A2 (enExample) |
| ZA (1) | ZA986517B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102789754B1 (ko) * | 2016-01-06 | 2025-03-31 | 론자 리미티드 | 개선된 생산을 위한 단백질 분해의 억제 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234686A (en) * | 1985-04-03 | 1993-08-10 | Beecham Group P.L.C. | Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment |
| US5094953A (en) * | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
| DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
| DE3907679A1 (de) * | 1989-03-09 | 1990-09-13 | Max Planck Gesellschaft | Verfahren zur gezielten veraenderung eines gens |
| JPH0576361A (ja) * | 1990-05-10 | 1993-03-30 | Takeda Chem Ind Ltd | 組織プラスミノーゲンアクチベータームテイン |
| US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
| WO1992020808A1 (en) * | 1991-05-15 | 1992-11-26 | Cell Genesys, Inc. | Genomic modifications with homologous dna targeting |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| DE69333955D1 (de) * | 1992-04-24 | 2006-02-02 | Stanford Res Inst Int | Targeting homologer sequenzen in eukaryotenzellen |
| WO1994004032A1 (en) * | 1992-08-21 | 1994-03-03 | The Regents Of The University Of California | Composition and method for altering dna sequences by homologous recombination |
| TW402639B (en) * | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| CN1256986C (zh) * | 1993-12-02 | 2006-05-24 | 转移染色体治疗公司 | 蛋白质的生产和蛋白质的输送 |
| AU6328696A (en) * | 1995-06-07 | 1996-12-30 | Yale University | Treatment of hemoglobinopathies |
| US6087129A (en) * | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
-
1998
- 1998-07-22 WO PCT/EP1998/004583 patent/WO1999005264A2/de not_active Ceased
- 1998-07-22 ES ES98942591T patent/ES2255177T5/es not_active Expired - Lifetime
- 1998-07-22 AT AT98942591T patent/ATE313643T1/de active
- 1998-07-22 PT PT98942591T patent/PT1000167E/pt unknown
- 1998-07-22 DK DK98942591.3T patent/DK1000167T4/da active
- 1998-07-22 JP JP2000504239A patent/JP2001511341A/ja active Pending
- 1998-07-22 BR BR9811531-6A patent/BR9811531A/pt not_active Application Discontinuation
- 1998-07-22 KR KR10-2000-7000697A patent/KR100512018B1/ko not_active Expired - Lifetime
- 1998-07-22 CA CA2297660A patent/CA2297660C/en not_active Expired - Lifetime
- 1998-07-22 US US09/463,338 patent/US6444441B1/en not_active Expired - Lifetime
- 1998-07-22 CN CN200810130044.0A patent/CN101348789B/zh not_active Expired - Lifetime
- 1998-07-22 TR TR2000/00172T patent/TR200000172T2/xx unknown
- 1998-07-22 EP EP98942591A patent/EP1000167B2/de not_active Expired - Lifetime
- 1998-07-22 CN CN98807438A patent/CN1265152A/zh active Pending
- 1998-07-22 DE DE59813296T patent/DE59813296D1/de not_active Expired - Lifetime
- 1998-07-22 ZA ZA9806517A patent/ZA986517B/xx unknown
- 1998-07-22 AU AU90673/98A patent/AU729489B2/en not_active Expired
- 1998-07-23 AR ARP980103617A patent/AR013251A1/es active IP Right Grant
-
2002
- 2002-07-15 US US10/194,244 patent/US20020177195A1/en not_active Abandoned
-
2008
- 2008-08-20 AR ARP080103620A patent/AR068104A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU9067398A (en) | 1999-02-16 |
| AR013251A1 (es) | 2000-12-13 |
| US20020068318A1 (en) | 2002-06-06 |
| ATE313643T1 (de) | 2006-01-15 |
| EP1000167B1 (de) | 2005-12-21 |
| BR9811531A (pt) | 2000-08-22 |
| DK1000167T3 (da) | 2006-04-24 |
| PT1000167E (pt) | 2006-05-31 |
| DE59813296D1 (de) | 2006-01-26 |
| CN101348789B (zh) | 2016-08-17 |
| ES2255177T3 (es) | 2006-06-16 |
| US6444441B1 (en) | 2002-09-03 |
| CN1265152A (zh) | 2000-08-30 |
| EP1000167A2 (de) | 2000-05-17 |
| EP1000167B2 (de) | 2011-04-20 |
| WO1999005264A2 (de) | 1999-02-04 |
| CN101348789A (zh) | 2009-01-21 |
| TR200000172T2 (tr) | 2000-12-21 |
| CA2297660C (en) | 2010-04-27 |
| ES2255177T5 (es) | 2011-07-12 |
| KR20010022127A (ko) | 2001-03-15 |
| US20020177195A1 (en) | 2002-11-28 |
| ZA986517B (en) | 2000-01-24 |
| AR068104A2 (es) | 2009-11-04 |
| AU729489B2 (en) | 2001-02-01 |
| CA2297660A1 (en) | 1999-02-04 |
| JP2001511341A (ja) | 2001-08-14 |
| WO1999005264A3 (de) | 1999-04-22 |
| DK1000167T4 (da) | 2011-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100233781B1 (ko) | 동종 재조합을 이용하는 단백질 제조방법 | |
| KR100379356B1 (ko) | 상동재조합을달성하기위한dna구성물및이것의용도 | |
| JP4138479B2 (ja) | 動物細胞に使用する発現ベクター | |
| US6291243B1 (en) | P element derived vector and methods for its use | |
| Bernard et al. | Construction of a fusion gene that confers resistance against hygromycin B to mammalian cells in culture | |
| EP3954774A1 (en) | Rna site-directed editing using artificially constructed rna editing enzymes and related uses | |
| JP3121611B2 (ja) | 神経成長因子を真核生物細胞において発現させるための遺伝子ベクター | |
| KR20000075788A (ko) | 유전자 치료에 의한 염증 세포의 자가-조절된 아포토시스 | |
| KR20170132784A (ko) | 글로빈 유전자 클러스터의 조절 요소를 포함하는 진핵생물 발현 벡터 | |
| WO1997023639A1 (en) | Process for producing biologically active fused proteins | |
| JPH0463595A (ja) | ヒトインターロイキン３誘導体 | |
| KR100512018B1 (ko) | 상동 재조합에 의해 인간 세포에서 인간 변이 단백질을 생성시키는 방법 | |
| KR20010086587A (ko) | 유전자 요법에 의한 염증성 세포의 자기-조절된 고사 | |
| EP0167852A2 (en) | Human interferon-gamma | |
| JPH11502705A (ja) | 哺乳動物細胞における遺伝子発現 | |
| MXPA00000645A (es) | Produccion de proteinas mutadas humanas en celulas humanas por medio de recombinacion homologa | |
| JPH0638773A (ja) | 薬剤耐性構造タンパク質遺伝子を選択遺伝子として用いた発現ベクター | |
| KR19990072793A (ko) | Ｄｎａ서열의유전자수송을위한아데노바이러스전달벡터 | |
| HK40060164A (en) | Rna site-directed editing using artificially constructed rna editing enzymes and related uses | |
| US20030082675A1 (en) | Transkaryotic delivery of therapeutic products | |
| Hentschel | Recent developments in mammalian expression systems | |
| JPH03136000A (ja) | 糖鎖を有するｂ細胞分化因子 | |
| EP2912173A1 (en) | Process for preparation and purification of recombinant human oncostatin m protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20000121 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20030602 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20041224 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050620 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050825 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20050826 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20080814 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090819 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100818 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110818 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20120820 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120820 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20130816 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130816 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20140814 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140814 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20150813 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150813 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20160811 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160811 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20170817 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170817 Start annual number: 13 End annual number: 13 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20190122 Termination category: Expiration of duration |